| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 141 | METHODS FOR SYNTHESIZING KOTALANOL AND STEREOISOMERS AND ANALOGUES THEREOF, AND NOVEL COMPOUNDS PRODUCED THEREBY | US12934898 | 2009-03-25 | US20110268822A1 | 2011-11-03 | Brian Mario Pinto; Jayakanthan Kumarasamy; Ravindranath Nasi; Sankar Mohan |
| Compounds having the general formula (I): wherein X is S, Se or NH, and stereoisomers thereof, and de-O-sulfonated analogues of all of the foregoing, but excluding naturally occurring kotalanol and de-O-sulfonated kotalanol, and methods for synthesizing same. The compounds are useful as glycosidase inhibitors, and may be used in the treatment of diabetes. The synthetic compounds may also be used as standards in the calibration or grading of natural or herbal remedies produced from natural sources of glycosidase inhibitors such as kotalanol. | ||||||
| 142 | Heterocyclic fused selenophene monomers | US11777362 | 2007-07-13 | US07982055B2 | 2011-07-19 | Steffen Zahn; Carrie A. Costello; Mark McLaws |
| A heterocyclic fused selenophenes and a method of making a heterocyclic fused selenophenes of formula (1): wherein X is S or Se, Y is S or Se, wherein one or both of X and Y is Se, R is a substituent group. The monomer being capable of polymerization to form an electrically conductive polymer or oligomer. | ||||||
| 143 | 2,5-DIARYL SELENOPHENE COMPOUNDS, AZA 2,5-DIARYL THIOPHENE COMPOUNDS, AND THEIR PRODRUGS AS ANTIPROTOZOAL AGENTS | US12680844 | 2008-10-17 | US20100331368A1 | 2010-12-30 | Richard R. Tidwell; David W. Boykin; Chad E. Stephens; Mohamed A. Ismail; Arvind Kumar; W. David Wilson; Reto Brun; Karl Werbovetz |
| Novel dicationic 2,5-diaryl selenophene compounds are described. Also described are novel aza analogues of dicationic 2,5-diaryl thiophenes. The presently disclosed dicationic compounds exhibit in vitro activity versus Trypanosoma brucei rhodesiense, Plasmodium falciparum, and/or Leishmania donovani comparable to that of pentamidine and furamidine. Some of the novel dicationic compounds display good activity in vivo in a murine model of a Trypanosoma brucei rhodesiense infection. | ||||||
| 144 | Organoselenium compound for cancer chemoprevention | US11980875 | 2007-10-31 | US07855232B2 | 2010-12-21 | Luke K. T. Lam; Nayaz Ahmed |
| A compound containing an alkylene selenocyanate or an alkylene isoselenocyanate moiety effective to prevent the occurrence or progression of cancer or a precancerous condition. The compound can be provided and administered in the form of a pharmaceutical composition, a cosmetic, a food additive, supplement, or the like. Methods for synthesis and use of the chemopreventive compound of the invention are also provided. | ||||||
| 145 | Imaging agents | US11425078 | 2006-06-19 | US07837982B2 | 2010-11-23 | Mark M. Goodman |
| The present invention provides novel amino acid compounds useful in detecting and evaluating brain and body tumors. These compounds have the advantageous properties of rapid uptake and prolonged retention in tumors and can be labeled with halogen isotopes such as fluorine-18, iodine-123, iodine-124, iodine-125, iodine-131, bromine-75, bromine-76, bromine-77, bromine-82, astatine-210, astatine-211, and other astatine isotopes. These compounds can also be labeled with technetium and rhenium isotopes using known chelation complexes. The compounds disclosed herein bind tumor tissues in vivo with high specificity and selectivity when administered to a subject. Preferred compounds show a target to non-target ratio of at least 2:1, are stable in vivo and substantially localized to target within 1 hour after administration. Preferred compounds include 1-amino-2-[18F]fluorocyclobutyl-1-carboxylic acid (2-[18F]FACBC) and 1-amino-2-[18F]fluoromethylcyclobutyl-1-carboxylic acid (2-[18F]FMACBC). The labeled amino acid compounds of the invention are useful as imaging agents in detecting and/or monitoring tumors in a subject by PET or SPECT. | ||||||
| 146 | SELENOPHENES AND SELENOPHENE-BASED POLYMERS, THEIR PREPARATION AND USES THEREOF | US12677364 | 2008-09-10 | US20100283040A1 | 2010-11-11 | Michael Bendikov; Asit Patra; Yair-Haim Wijsboom; Mao Li; Yana Sheynin; Natalia Zamoshchik; Sanjio S. Zade |
| This invention is directed to selenophene compounds, selenophene-based polymers (polyselenophene), processes for the preparation of the same and uses thereof. The polyselenophenes of this invention have high conductivity and can be used as electrodes in various devices such as in electrochromic devices, batteries, solar cells, optical amplifiers, organic light emitting diodes, and the like. | ||||||
| 147 | Mono-, oligo- and polythieno[3,2-b]thiophenes | US11596850 | 2005-04-21 | US07714098B2 | 2010-05-11 | Martin Heeney; Robert Wagner; Iain McCulloch; Steven Tierney |
| The invention relates to novel mono-, oligo- and polythieno[3,2-b]thiophenes, to their use as semiconductors or charge transport materials, in optical, electro-optical or electronic devices like for example liquid crystal displays, optical films, organic field effect transistors (FET or OFET) for thin film transistor liquid crystal displays and integrated circuit devices such as RFID tags, electroluminescent devices in flat panel displays, and in photovoltaic and sensor devices, and to field effect transistors, light emitting devices or ID tags comprising the novel polymers. | ||||||
| 148 | BIBENZOTHIOPHENE DERIVATIVES | US12123648 | 2008-05-20 | US20090292130A1 | 2009-11-26 | Jianmin Shi; Eric W. Forsythe; David C. Morton |
| Compounds containing bibenzochalcogenophene structures are provided in which the chalcogenide is sulfur, selenium, or tellurium. The compounds are characterized by planarity, rigid conjugation structure and high charge mobility making them useful as organic semiconductor in optical devices, electronic devices and integrated devices like organic field effect transistors (OFET) for thin film transistor liquid crystal display (LCD), electrophoretic display such as electronic paper, organic light emitting diode (OLED) for flat panel displays, organic radio frequency identification (ORFID) tags, organic photovoltaic (OPV), sensor devices, and analog and digital electronics. | ||||||
| 149 | Heterocyclic Fused Selenophene Monomers | US12353609 | 2009-01-14 | US20090143599A1 | 2009-06-04 | Steffen Zahn; Richard V.C. Carr; Roberta Kathleen Hause; Carrie A. Costello; Mark Mclaws |
| A heterocyclic fused selenophenes and a method of making a heterocyclic fused selenophenes of formula (1): wherein X is S or Se, Y is S or Se, wherein one or both of X and Y is Se, R is a substituent group. The monomer being capable of polymerization to form an electrically conductive polymer or oligomer. | ||||||
| 150 | Organoselenium compound for cancer chemoprevention | US11980875 | 2007-10-30 | US20080108692A1 | 2008-05-08 | Luke Lam; Nayaz Ahmed |
| A compound containing an alkylene selenocyanate or an alkylene isoselenocyanate moiety effective to prevent the occurrence or progression of cancer or a precancerous condition. The compound can be provided and administered in the form of a pharmaceutical composition, a cosmetic, a food additive, supplement, or the like. Methods for synthesis and use of the chemopreventive compound of the invention are also provided. | ||||||
| 151 | Organoselenium compounds for cancer chemoprevention | US11263808 | 2005-11-01 | US07314929B2 | 2008-01-01 | Luke K. T. Lam; Nayaz Ahmed |
| A compound containing an alkylene selenocyanate or an alkylene isoselenocyanate moiety effective to prevent the occurrence or progression of cancer or a precancerous condition. The compound can be provided and administered in the form of a pharmaceutical composition, a cosmetic, a food additive, supplement, or the like. Methods for synthesis and use of the chemopreventive compound of the invention are also provided. | ||||||
| 152 | Mono-, Oligo- and Polythieno [3,2-B]Thiophenes | US11596850 | 2005-04-21 | US20070232812A1 | 2007-10-04 | Martin Heeney; Robert Wagner; Iain McCulloch; Steven Tierney |
| The invention relates to novel mono-, oligo- and polythieno[3,2-b]thiophenes, to their use as semiconductors or charge transport materials, in optical, electro-optical or electronic devices like for example liquid crystal displays, optical films, organic field effect transistors (FET or OFET) for thin film transistor liquid crystal displays and integrated circuit devices such as RFID tags, electroluminescent devices in flat panel displays, and in photovoltaic and sensor devices, and to field effect transistors, light emitting devices or ID tags comprising the novel polymers. | ||||||
| 153 | Novel bichalcophenes and their prodrugs as antiprotozoal agents | US11435323 | 2006-05-16 | US20060293540A1 | 2006-12-28 | Richard Tidwell; David Boykin; Chad Stephens; Mohamed Ismail; W. Wilson; Reto Brun; Karl Werbovetz |
| Novel dicationic bichalcophene compounds are described. The presently disclosed novel dicationic bichalcophene compounds exhibit in vitro activity versus Trypanosoma brucei rhodesiense, Plasmodium falciparum, or Leishmania donovani comparable to that of pentamidine and furamidine. Some of the novel dicationic bichalcophene compounds displayed good activity in vivo in a murine model of a Trypanosoma brucei rhodesiense infection. | ||||||
| 154 | Selenophene anti-tumor agents | US11103991 | 2005-04-12 | US20050203077A1 | 2005-09-15 | Ching-jer Chang; Curtis Ashendel; Darrick Kim |
| Novel selenophene compounds useful as anti-tumor agents are described. Preferred compounds include compounds of formula I: wherein R1 and R2 are independently selected from the group consisting of H, CHO, CH2OH and CH2NH2; and X and Y are independently selected from the group consisting of Se, S, O, NCH3, and NH. Pharmaceutical compositions and a method for treating patients having tumors utilizing the disclosed selenophene compounds are also described. | ||||||
| 155 | Utilization of heteroarene carboxamide as dopamine-d3 ligands for the treatment of cns diseases | US10519487 | 2003-07-02 | US20050197343A1 | 2005-09-08 | Peter Gmeiner; Harald Hubner; Karin Schlotter |
| The invention relates to neuroreceptor active N-[(4-phenyl-1-piperazinyl)alkyl]-substituted heteroarene carboxamide of general formula (I) and to structure analogous 2-ferrocenyl compounds of general formula (II) and the utilization thereof for the treatment of CNS diseases, for example, schizophrenia, different forms of depression, neurodegenerative disorders, sexual dysfunctions, cocaine, alcohol, opiate and nicotine addiction, in addition to glaucoma, cognitive disorders, restless leg syndrome, hyperactivity syndrome (ADHS), hyperprolactinemia, hyperprolactinoma, locomotion disorders associated with Parkinson's disease, treatment of L-DOPA and neuroleptic-induced locomotion disorders, for example, akathisia, rigor, dystonia and dyskinesia, wherein the substituents are defined in the description. | ||||||
| 156 | Pyruvate derivatives | US10138937 | 2002-05-03 | US06916850B2 | 2005-07-12 | Bing Wang; Guy Miller; Wei Zhang |
| Certain known and novel pyruvate derivatives are particularly active in restoring or preserving metabolic integrity in oxidatively competent cells that have been subjected to oxygen deprivation. These pyruvate-derived compounds include, but are not limited to oximes, amides, pyruvate analogues, modified pyruvate analogues, esters of pyruvate (e.g., polyol-pyruvate esters, pyruvate thioesters, glycerol-pyruvate esters and dihydroxyacetone-pyruvate esters). Such pyruvate derivatives (including single tautomers, single stereoisomers and mixtures of tautomers and/or stereoisomers, and the pharmaceutically acceptable salts thereof) are useful in the manufacture of pharmaceutical compositions for treating a number of conditions characterized by oxidative stress. | ||||||
| 157 | Pyruvate derivatives | US10138938 | 2002-05-03 | US06900218B2 | 2005-05-31 | Bing Wang; Guy Miller; Satyanarayana Janagani |
| Certain known and novel pyruvate derivatives are particularly active in restoring or preserving metabolic integrity in oxidatively competent cells that have been subjected to oxygen deprivation. These pyruvate-derived compounds include, but are not limited to oximes, amides, pyruvate analogues, modified pyruvate analogues, esters of pyruvate (e.g., polyol-pyruvate esters, pyruvate thioesters, glycerol-pyruvate esters and dihydroxyacetone-pyruvate esters). Such pyruvate derivatives (including single tautomers, single stereoisomers and mixtures of tautomers and/or stereoisomers, and the pharmaceutically acceptable salts thereof) are useful in the manufacture of pharmaceutical compositions for treating a number of conditions characterized by oxidative stress. | ||||||
| 158 | Selenium-containing transparent optical material | US10246405 | 2002-09-19 | US06664364B2 | 2003-12-16 | Koju Okazaki; Mamoru Tanaka; Shiro Honma; Hiroyuki Morijiri; Yoshinobu Kanemura; Masahiko Kusumoto |
| There are herein disclosed a transparent optical material containing at least one selenium atom, a plastic lens comprising the transparent optical material, and methods for preparing them. In addition, there are also disclosed novel selenium-containing compounds represented by the following formulae (1), (2) and (4) which are useful for the transparent optical material and the plastic lens: wherein symbols are as defined in the specification. | ||||||
| 159 | Pyruvate derivatives | US10138938 | 2002-05-03 | US20030013657A1 | 2003-01-16 | Bing Wang; Guy Miller; Satyanarayana Janagani |
| Certain known and novel pyruvate derivatives are particularly active in restoring or preserving metabolic integrity in oxidatively competent cells that have been subjected to oxygen deprivation. These pyruvate-derived compounds include, but are not limited to oximes, amides, pyruvate analogues, modified pyruvate analogues, esters of pyruvate (e.g., polyol-pyruvate esters, pyruvate thioesters, glycerol-pyruvate esters and dihydroxyacetone-pyruvate esters). Such pyruvate derivatives (including single tautomers, single stereoisomers and mixtures of tautomers and/or stereoisomers, and the pharmaceutically acceptable salts thereof) are useful in the manufacture of pharmaceutical compositions for treating a number of conditions characterized by oxidative stress. | ||||||
| 160 | Organoselenium compounds for cancer chemoprevention | US10081297 | 2002-02-20 | US20020165215A1 | 2002-11-07 | Luke K.T. Lam; Nayaz Ahmed |
| A compound containing an alkylene selenocyanate or an alkylene isoselenocyanate moiety effective to prevent the occurrence or progression of cancer or a precancerous condition. The compound can be provided and administered in the form of a pharmaceutical composition, a cosmetic, a food additive, supplement, or the like. Methods for synthesis and use of the chemopreventive compound of the invention are also provided. | ||||||
QQ群二维码
意见反馈
意见反馈